Latest S-1 registration statements

VivoSim Labs, Inc. files an S-1/A for a best efforts public offering of up to $4 million in common stock and warrants, aiming to fund operations through 2027 despite significant accumulated losses and auditor's going concern warning.

VivoSim Labs, a biotech services firm, is conducting a best efforts public offering of up to $4 million in common stock and warrants to fund operations, despite an auditor's 'going concern' warning and significant accumulated losses.

FibroBiologics, Inc. announces a public offering of common stock and warrants to raise capital and address ongoing Nasdaq listing compliance issues, including a recent 1-for-20 reverse stock split.

Selling shareholders of WaterBridge Infrastructure LLC are offering up to 83,250,000 Class A shares, with the company receiving no proceeds from the resale.

Ideal Power Inc. filed an S-1 registration statement for the potential resale of 631,332 shares of common stock by a selling securityholder, issuable upon exercise of pre-funded warrants.

First Choice Healthcare Solutions, Inc. is undergoing a major strategic shift from orthopedics to a national chain of primary care and wellness clinics, aiming to raise up to $19 million in a public offering.

CIMG Inc. is seeking to raise up to $650 million through a direct offering of units and warrants, payable in cash or Bitcoin, as it navigates a recent delisting from Nasdaq and shifts its business focus to health and AI products in Asia.

VenHub Global, an autonomous retail technology company, filed an S-1 registration statement for the resale of up to 16.485 million common shares by existing stockholders, reporting significant net losses and a going concern opinion.

Artelo Biosciences files an S-1 registration statement for the resale of up to 4.27 million common shares by Square Gate Capital, potentially accessing up to $50 million in future equity financing.

Forgent Power Solutions, Inc. is undertaking a follow-on public offering of Class A Common Stock to fund the redemption of Opco LLC Interests from existing equity owners.

Artelo Biosciences, a clinical-stage biopharmaceutical company, is conducting a best-efforts public offering to raise up to $10.9 million while addressing Nasdaq listing compliance issues and reporting positive interim clinical trial data.

Netcapital Inc. is registering shares for resale and seeking up to $9.21 million from warrant exercises while grappling with a Nasdaq minimum bid price deficiency and an ongoing SEC enforcement investigation.

Encore Medical, a structural heart device company, is launching an IPO to raise approximately $12.7 million to finance U.S. clinical trials for its PFO septal occlusion device for stroke and migraine indications, aiming for a NYSE American listing.

Artelo Biosciences files an S-1/A for a best efforts public offering of up to 1.64M shares and warrants to raise capital and address a Nasdaq listing deficiency.

AI Era Corp. filed an S-1 registration statement for the potential resale of up to 10.1 million shares by Monroe Street Capital Partners, LP, while outlining its strategic shift to AI-driven content and addressing significant financial and operational risks.

HMH Holding Inc. announces its initial public offering of 10.52 million Class A common shares, aiming to reduce debt and capitalize on a recovering offshore and international onshore oil and gas market.

AIAI Holdings Corporation files an amended S-1 registration statement for a direct listing on Nasdaq, aiming to create an AI-powered ecosystem through strategic acquisitions.

Cyabra Inc. (formerly Trailblazer Holdings, Inc.) has completed its business combination, listing on Nasdaq, but faces significant operating losses and a going concern doubt.

GoPro, Inc. has filed an S-1 registration statement for the resale of up to 120 million shares of Class A common stock by a selling stockholder, YA II PN, Ltd., stemming from convertible debentures.

Artelo Biosciences, a clinical-stage biopharmaceutical company, is offering up to 1.64 million shares and pre-funded warrants to raise capital, primarily for working capital and to address Nasdaq listing deficiencies.

QDRO Acquisition Corp., a blank check company, filed an S-1/A for its $200 million initial public offering, targeting financial services and digital currency sectors, while facing significant dilution risks and a 'going concern' uncertainty.

SolarWindow Technologies, Inc. filed an S-1/A amendment for the resale of over 25 million shares by existing stockholders, while emphasizing its pre-revenue stage, ongoing losses, and critical need for future financing to commercialize its transparent electricity-generating technology.

Papa Medical Inc. is pursuing an initial public offering of 3.75 million Class A common shares at $4.00 per share, aiming to raise $12.8 million, while facing significant regulatory changes impacting a substantial portion of its Hemp cannabinoid E-vapors business.

Eagle Nuclear Energy Corp. filed an S-1 registration statement for a primary and secondary offering of common stock and warrants, following its business combination and acquisition of the Aurora Uranium Project.

Little West Holdings Inc. filed an S-1/A for its initial public offering, seeking to list 3.75 million shares on Nasdaq at an estimated price of $4.00 to $6.00 per share, despite a history of net losses and a going concern doubt.

GivBux, Inc. reports continued net losses and a significant accumulated deficit, relying on convertible debt financing while redesigning its Super App for a Q1 2026 release.

Albert Origin Acquisition Corporation, a blank check company, filed an S-1/A for a $60 million IPO, outlining its search for a business combination while navigating significant risks related to its management's ties to China and its current financial deficit.

Pine Tree Acquisition Corp., a blank check company, filed an S-1/A detailing its $100 million initial public offering of units, each comprising one Class A ordinary share and one-tenth of a right, as it seeks a business combination.

Presidio Production Company has successfully completed its business combination with EQV Ventures Acquisition Corp., raising significant capital and listing on the NYSE under 'FTW'.

Option Therapeutics Inc., a BioVie subsidiary, is launching its initial public offering to fund the Phase 3 clinical trial of BIV201, an investigational drug for advanced liver cirrhosis complications, aiming to raise $17.0 million.